Cargando…
Safety surveillance and challenges in accelerated COVID-19 vaccine development
The COVID-19 pandemic, caused by a novel type of coronavirus, continues to infect people, increasing morbidity and mortality across the globe. Measures to slow the transmission of the virus have had limited impact, and people, businesses, and economies have suffered. The disease has disproportionall...
Autores principales: | Cole, Abimbola, Webster, Peggy, Van Liew, Denny, Salas, Maribel, Aimer, Omar, Malikova, Marina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444812/ https://www.ncbi.nlm.nih.gov/pubmed/36072284 http://dx.doi.org/10.1177/20420986221116452 |
Ejemplares similares
-
The Use of Biomarkers in Pharmacovigilance: A Systematic Review of the Literature
por: Salas, Maribel, et al.
Publicado: (2023) -
Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities
por: Kugener, Veronique F., et al.
Publicado: (2021) -
Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests
por: Eyal, Nir, et al.
Publicado: (2021) -
Safety and reactogenicity of the adjuvanted recombinant zoster
vaccine: experience from clinical trials and post-marketing
surveillance
por: Fiore, Joseph, et al.
Publicado: (2021) -
An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP)
por: Gossell-Williams, Maxine, et al.
Publicado: (2021)